*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>BTS 44595 is a selective <strong>CCR8 antagonist</strong> developed for oncology and autoimmune research. It functions by blocking C-C chemokine receptor type 8 to inhibit leukocyte migration. The compound features the molecular formula <strong>C26H28N4O3S</strong> with CAS registry number <strong>1770698-87-9</strong>.</p>
<h3>Application</h3>
<ul>
<li><strong>Oncology Research:</strong> Investigating tumor microenvironment modulation.</li>
<li><strong>Autoimmune Studies:</strong> Evaluating efficacy in inflammatory disease models.</li>
<li><strong>Drug Discovery:</strong> Utilized as a chemical probe for target validation.</li>
</ul>
<h3>Precautions</h3>
<p>Strictly for <strong>in vitro</strong> or preclinical use only; not approved for human clinical therapy. Store under <strong>-20°C</strong> in desiccated conditions. Handle with appropriate PPE to avoid dermal exposure.</p>